• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

二甲双胍改善2型糖尿病合并心力衰竭患者的血糖控制和餐后代谢并增强餐后胰高血糖素样肽-1分泌：一项随机、双盲、安慰剂对照试验

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial.

作者信息

Melenovský Vojtěch, Hošková Eva, Velebová Kateřina, Veleba Jiří, Borlaug Barry A, Benes Jan, Kuda Ondřej, Čajka Tomáš, Segeťová Markéta, Thieme Lenka, Kopecký Jan, Kopecký Jan, Pelikánová Terezie, Haluzík Martin, Hill Martin, Kahleová Hana

机构信息

Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.

出版信息

Clin Diabetes. 2024 Sep 9;43(1):23-32. doi: 10.2337/cd24-0003. eCollection 2025 Winter.

DOI:10.2337/cd24-0003
PMID:39829685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11739370/
Abstract

This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.

摘要

这项随机试验测试了二甲双胍对心力衰竭（HF）合并2型糖尿病患者血糖控制和心脏功能的影响，同时评估了肠道对由氧化三甲胺（TMAO）和肠道源性肠促胰岛素反映的特定肠道微生物群产物的影响。二甲双胍治疗改善了血糖控制和餐后代谢，并增强了餐后胰高血糖素样肽1（GLP-1）的分泌，但未影响心脏功能或TMAO水平。二甲双胍在HF中的代谢作用可能是通过改善肠道内分泌功能和增强肠道源性肠促胰岛素GLP-1的分泌来介导的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57a5/11739370/4fe872309488/diaclincd240003f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57a5/11739370/86cff9cd9ea4/diaclincd240003f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57a5/11739370/4fe872309488/diaclincd240003f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57a5/11739370/86cff9cd9ea4/diaclincd240003f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/57a5/11739370/4fe872309488/diaclincd240003f2.jpg

相似文献

1
Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial.二甲双胍改善2型糖尿病合并心力衰竭患者的血糖控制和餐后代谢并增强餐后胰高血糖素样肽-1分泌：一项随机、双盲、安慰剂对照试验
Clin Diabetes. 2024 Sep 9;43(1):23-32. doi: 10.2337/cd24-0003. eCollection 2025 Winter.
2
The role of glucagon-like peptide 1 in the postprandial effects of metformin in type 2 diabetes: a randomized crossover trial.胰高血糖素样肽 1 在二甲双胍治疗 2 型糖尿病餐后效应中的作用：一项随机交叉试验。
Eur J Endocrinol. 2024 Aug 5;191(2):192-203. doi: 10.1093/ejendo/lvae095.
3
EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.EndoBarrier胃肠道内衬。潜在机制及临床效果的描述。
Dan Med J. 2016 Nov;63(11).
4
Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.在二甲双胍治疗的 2 型糖尿病患者中，使用长效 GLP-1 类似物替西帕肽治疗 8 周可改善餐后胰岛素分泌和敏感性。
Metabolism. 2013 Sep;62(9):1330-9. doi: 10.1016/j.metabol.2013.05.001. Epub 2013 Jul 4.
5
Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study.二甲双胍给药时机对 2 型糖尿病患者经十二指肠内葡萄糖输注后血糖和胰高血糖素样肽-1 反应的影响：一项双盲、随机、安慰剂对照、交叉研究。
Diabetologia. 2024 Jul;67(7):1260-1270. doi: 10.1007/s00125-024-06131-6. Epub 2024 Apr 1.
6
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.蛋白负荷可增强维格列汀在 2 型糖尿病患者中的降糖疗效。
Diabetes Care. 2016 Apr;39(4):511-7. doi: 10.2337/dc15-2298. Epub 2016 Jan 19.
7
Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes.阿卡波糖可减轻 2 型糖尿病患者餐后骨吸收抑制作用。
Bone. 2023 May;170:116687. doi: 10.1016/j.bone.2023.116687. Epub 2023 Feb 6.
8
Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes.二甲双胍诱导的胰高血糖素样肽-1 分泌有助于二甲双胍在 2 型糖尿病中的作用。
JCI Insight. 2018 Dec 6;3(23):93936. doi: 10.1172/jci.insight.93936.
9
Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.十二周的 DPP-4 抑制剂西他列汀治疗可防止 2 型糖尿病患者肽 YY 的降解，并改善葡萄糖和非葡萄糖诱导的胰岛素分泌。
Diabetes Obes Metab. 2010 Apr;12(4):323-33. doi: 10.1111/j.1463-1326.2009.01167.x.
10
Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.艾塞那肽：一种用于治疗2型糖尿病的肠促胰岛素类似物。
Clin Ther. 2006 May;28(5):652-65. doi: 10.1016/j.clinthera.2006.05.006.

本文引用的文献

1
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes: data from the Swedish Heart Failure and Swedish National Diabetes Registries.胰高血糖素样肽-1 受体激动剂在心力衰竭和 2 型糖尿病中的使用及其与结局的相关性：来自瑞典心力衰竭和瑞典国家糖尿病登记处的数据。
Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):296-306. doi: 10.1093/ehjcvp/pvae026.
2
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.司美格鲁肽治疗肥胖相关性心力衰竭合并 2 型糖尿病患者的效果。
N Engl J Med. 2024 Apr 18;390(15):1394-1407. doi: 10.1056/NEJMoa2313917. Epub 2024 Apr 6.
3
Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure.
二甲双胍与心脏：心血管保护机制的最新进展，特别提及2型糖尿病合并心力衰竭
Metabolism. 2022 May;130:155160. doi: 10.1016/j.metabol.2022.155160. Epub 2022 Feb 7.
4
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
5
Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study.二甲双胍可降低体重，但不能增加无糖尿病的慢性心力衰竭患者的胰岛素敏感性：一项随机、双盲、安慰剂对照研究。
Cardiovasc Drugs Ther. 2021 Jun;35(3):491-503. doi: 10.1007/s10557-020-07050-5. Epub 2020 Aug 8.
6
Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes.二甲双胍通过增加肠降血糖素而不改变糖异生改善 2 型糖尿病青少年的血糖。
Diabetologia. 2020 Oct;63(10):2194-2204. doi: 10.1007/s00125-020-05236-y. Epub 2020 Jul 29.
7
The gut microbiome in coronary artery disease and heart failure: Current knowledge and future directions.肠道微生物组与冠状动脉疾病和心力衰竭：现有知识和未来方向。
EBioMedicine. 2020 Feb;52:102649. doi: 10.1016/j.ebiom.2020.102649. Epub 2020 Feb 12.
8
A randomised, double-blind, placebo-controlled trial of metformin on myocardial efficiency in insulin-resistant chronic heart failure patients without diabetes.一项随机、双盲、安慰剂对照试验，研究二甲双胍对无糖尿病的胰岛素抵抗慢性心力衰竭患者心肌效率的影响。
Eur J Heart Fail. 2020 Sep;22(9):1628-1637. doi: 10.1002/ejhf.1656. Epub 2019 Dec 21.
9
Effects of Metformin on Left Ventricular Size and Function in Hypertensive Patients with Type 2 Diabetes Mellitus: Results of a Randomized, Controlled, Multicenter, Phase IV Trial.二甲双胍对 2 型糖尿病合并高血压患者左心室大小和功能的影响：一项随机、对照、多中心、四期临床试验的结果。
Am J Cardiovasc Drugs. 2020 Jun;20(3):283-293. doi: 10.1007/s40256-019-00381-1.
10
Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.二甲双胍对冠心病患者全因和心血管死亡率的影响：系统评价和更新的荟萃分析。
Cardiovasc Diabetol. 2019 Jul 30;18(1):96. doi: 10.1186/s12933-019-0900-7.